1. Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
- Author
-
Lobo, Suzana, Plantefève, Gaétan, Nair, Girish, Joaquim Cavalcante, Adilson, Franzin de Moraes, Nara, Nunes, Estevao, Barnum, Otis, Berdun Stadnik, Claudio, Lima, Maria, Lins, Muriel, Hajjar, Ludhmila, Lipinski, Christopher, Islam, Shaheen, Ramos, Fabiano, Simon, Tiago, Martinot, Jean-Benoît, Guimard, Thomas, Desclaux, Arnaud, Lioger, Bertrand, Neuenschwander, Fernando, DeSouza Paolino, Bruno, Acosta, Samuel, Dilling, Daniel, Cartagena, Edgardo, Snyder, Brian, Devaud, Edouard, Barreto Berselli Marinho, Ana, Tanni, Suzana, Milhomem Beato, Patricia, De Wit, Stephan, Selvan, Vani, Gray, Jeffrey, Fernandez, Ricardo, Pourcher, Valérie, Maddox, Lee, Kay, Richard, Azbekyan, Anait, Chabane, Mounia, Tourette, Cendrine, Esmeraldino, Luis, Dilda, Pierre, Lafont, René, Mariani, Jean, Camelo, Serge, Rabut, Sandrine, Agus, Samuel, Veillet, Stanislas, Dioh, Waly, van Maanen, Rob, Morelot-Panzini, Capucine, and Amin, Alpesh
- Subjects
20-Hydroxyecdysone ,COVID-19 ,MasR ,Renin-angiotensin-system (RAS) ,Respiratory failure ,SARS-CoV-2 - Abstract
BACKGROUND: SARS-CoV-2 binding to ACE2 is potentially associated with severe pneumonia due to COVID-19. The aim of the study was to test whether Mas-receptor activation by 20-hydroxyecdysone (BIO101) could restore the Renin-Angiotensin System equilibrium and limit the frequency of respiratory failure and mortality in adults hospitalized with severe COVID-19. METHODS: Double-blind, randomized, placebo-controlled phase 2/3 trial. Randomization: 1:1 oral BIO101 (350 mg BID) or placebo, up to 28 days or until an endpoint was reached. Primary endpoint: mortality or respiratory failure requiring high-flow oxygen, mechanical ventilation, or extra-corporeal membrane oxygenation. Key secondary endpoint: hospital discharge following recovery (ClinicalTrials.gov Number, NCT04472728). FINDINGS: Due to low recruitment the planned sample size of 310 was not reached and 238 patients were randomized between August 26, 2020 and March 8, 2022. In the modified ITT population (233 patients; 126 BIO101 and 107 placebo), respiratory failure or early death by day 28 was 11.4% lower in the BIO101 (13.5%) than in the placebo (24.3%) group, (p = 0.0426). At day 28, proportions of patients discharged following recovery were 80.1%, and 70.9% in the BIO101 and placebo group respectively, (adjusted difference 11.0%, 95% CI [-0.4%, 22.4%], p = 0.0586). Hazard Ratio for time to death over 90 days: 0.554 (95% CI [0.285, 1.077]), a 44.6% mortality reduction in the BIO101 group (not statistically significant). Treatment emergent adverse events of respiratory failure were more frequent in the placebo group. INTERPRETATION: BIO101 significantly reduced the risk of death or respiratory failure supporting its use in adults hospitalized with severe respiratory symptoms due to COVID-19. FUNDING: Biophytis.
- Published
- 2024